Nuvectra™ Announces Proposed Follow-On Stock Offering
January 31 2018 - 4:01PM
Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical
device company, announced today that it is commencing an
underwritten follow-on public offering of its common stock. In
addition, Nuvectra intends to grant the underwriters a 30-day
option to purchase additional shares of its common stock. Nuvectra
intends to use the net proceeds from this offering to fund the
expansion of product development and commercialization activities,
as well as for general corporate purposes.
Piper Jaffray is acting as sole book-running manager for the
offering. JMP Securities and SunTrust Robinson Humphrey are acting
as co-managers.
A shelf registration statement on Form S-3 (including a
prospectus) relating to these securities has been filed with
the Securities and Exchange Commission (“SEC”) and was
declared effective on October 24, 2017. A preliminary
prospectus supplement relating to the offering will also be filed
with the SEC. Before you invest, you should read the prospectus in
that registration statement, the preliminary prospectus supplement
and other documents the issuer has filed with the SEC for more
complete information about Nuvectra and this offering. Copies of
the preliminary prospectus related to the offering may be obtained
from Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis,
Minnesota 55402, by telephone at (800) 747-3924, and by e-mail
at prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Nuvectra Corporation
NuvectraTM is a neurostimulation company committed to helping
physicians improve the lives of people with chronic conditions. The
Algovita® Spinal Cord Stimulation (SCS) System is our first
commercial offering and is CE marked and FDA approved for the
treatment of chronic intractable pain of the trunk and/or limbs.
Our innovative technology platform also has capabilities under
development to support other indications such as sacral
neuromodulation (SNM) for the treatment of overactive bladder, and
deep brain stimulation (DBS) for the treatment of Parkinson’s
Disease. In addition, our NeuroNexus subsidiary designs,
manufactures and markets leading-edge neural-interface technologies
for the neuroscience clinical research market. Visit the Nuvectra
website at www.nuvectramed.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements," including statements we make regarding the outlook
for Nuvectra as an independent publicly-traded company.
Forward-looking statements are based only on our current beliefs,
expectations and assumptions regarding the future of our business,
future plans and strategies, projections, anticipated events and
trends, the economy and other future conditions, and therefore they
are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and may be outside of
our control. Our actual performance may differ materially from
those indicated in the forward-looking statements. Therefore, you
should not rely on any of these forward-looking statements. Any
forward-looking statement made by us is based only on information
currently available to us and speaks only as of the date on which
it is made. Important factors that could cause our actual
results to differ materially from those indicated in the
forward-looking statements include: (i) our ability to successfully
commercialize Algovita and to develop, complete and commercialize
enhancements or improvements to Algovita; (ii) our ability to
successfully compete with our current SCS competitors and the
ability of our U.S. sales representatives to successfully establish
market share and acceptance of Algovita, (iii) the uncertainty of
obtaining regulatory approvals in the United States and Europe for
our Virtis SNM system, (iv) our ability to successfully launch and
commercialize the Virtis SNM system if it receives regulatory
approval (v) our ability to demonstrate the features, perceived
benefits and capabilities of Algovita to physicians and patients in
competition with similar products already well established and sold
in the SCS market; (vi) our ability to anticipate and satisfy
customer needs and preferences and to develop, introduce and
commercialize new products or advancements and improvements to
Algovita in order to successfully meet our customers’ expectations;
(vii) the outcome of our development plans for our neurostimulation
technology platform, including our ability to identify additional
indications or conditions for which we may develop neurostimulation
medical devices or therapies and seek regulatory approval thereof;
(viii) our ability to identify business development and growth
opportunities and to successfully execute on our strategy,
including our ability to seek and develop strategic partnerships
with third parties to, among other things, fund clinical and
development costs for new product offerings; (ix) the performance
by our development partners, including Aleva
Neurotherapeutics, S.A., of their obligations under their
agreements with us; (x) the scope of protection for our
intellectual property rights covering Algovita and other products
using our neurostimulation technology platform, along with any
product enhancements or improvements; (xi) our ability to
successfully build, attract and maintain an effective commercial
infrastructure and qualified sales force in the United States;
(xii) our compliance with all regulatory and legal requirements
regarding implantable medical devices and interactions with
healthcare professionals; (xiii) any supplier shortages related to
Algovita or its components and any manufacturing disruptions which
may impact our inventory supply as we expand our business, (xiv)
any product recalls, or the receipt of any warning letters,
mandatory corrections or fines from any governmental or regulatory
agency; (xv) our ability to satisfy the conditions and covenants,
including trailing six month revenue milestones, of our Credit
Facility; and (xvi) our ability to raise capital through means
other than or in addition to the Credit Facility should it become
necessary to do so, through a public offering of our common stock,
private equity or debt financings, strategic partnerships, or other
sources. Please see the section entitled “Risk Factors” in
Nuvectra’s Annual Report on Form 10-K and in our other quarterly
and periodic filings for a description of these and other risks and
uncertainties. We undertake no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Company Contacts: Nuvectra
CorporationWalter Berger, COO & CFO (214)
474-3102wberger@nuvectramed.com
Investor Contacts:The Ruth Group
Tram Bui / Brian Johnston(646) 536-7035 / 7028
investors@nuvectramed.com
Nuvectra (NASDAQ:NVTR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuvectra (NASDAQ:NVTR)
Historical Stock Chart
From Jul 2023 to Jul 2024